Cancer Research Horizons
Cancer Research Horizons is a London-based organization dedicated to the development and commercialization of innovations in cancer research. Established in 1982, it serves as a critical connection between academia and industry, leveraging its deep understanding of both sectors to transform promising research into viable commercial solutions that benefit patients while maximizing financial returns. The organization is uniquely positioned to draw on the extensive research and partnerships fostered by its parent entity, Cancer Research UK, the leading charitable funder of cancer research globally. With over 30 years of specialized experience, Cancer Research Horizons has a proven track record in advancing cancer therapeutics, diagnostics, and related technologies. Its team, comprised of experienced and motivated professionals, is divided between drug discovery and commercialization, ensuring a comprehensive approach to delivering breakthrough therapies to patients.
Top Stages
10 past transactions
52 North
Venture Round in 2024
52 North Health is a medical technology company focused on enhancing healthcare outcomes for cancer patients. It specializes in an AI-driven, portable finger prick blood test that measures neutrophil count and C-reactive protein (CRP) levels at home. This enables early detection of neutropenic sepsis risk during chemotherapy, improving patient safety and quality of life. The device facilitates timely management of the condition, offering a reliable and cost-effective solution for both patients and healthcare providers.
Infinitopes
Seed Round in 2024
Infinitopes is a biotechnology company dedicated to advancing cancer research with the aim of strengthening patients' immune systems to prevent metastases and improve outcomes. The company's platform integrates high-efficiency vector delivery systems with optimal tumor target identification technologies, enabling early-stage clinical trials that could potentially save lives by preventing cancer progression.
Neobe Therapeutics
Seed Round in 2024
Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services.
Trogenix
Seed Round in 2024
Trogenix operates as a therapeutics company, that treats aggressive cancers.
NK:IO
Seed Round in 2023
NK:IO is a biotechnology company focused on advancing innovative strategies for natural killer cell-mediated immunotherapy. It specializes in the development of both cell therapies and small molecule therapeutics, with a primary emphasis on cancer treatment. By harnessing the capabilities of natural killer cells, NK:IO aims to enhance the effectiveness of cancer therapies, providing physicians with improved tools to combat the disease. The company's commitment to research and development positions it at the forefront of immunotherapy advancements in the oncology field.
Elaitra
Pre Seed Round in 2023
Elaitra is a healthcare technology company focused on advancing breast cancer detection through innovative imaging solutions. It has developed a digital breast tomosynthesis imaging platform that utilizes artificial intelligence to enhance the interpretation of 3D X-rays. This platform includes a unique AI reading tool and a viewing assistant that aids physicians in diagnosing and triaging breast cancer, facilitating earlier detection and treatment. Elaitra's technologies have received regulatory approvals from the FDA in the United States and relevant authorities in the United Kingdom. Additionally, the company incorporates a Generative LLM for voice-based patient engagement, further enriching the patient experience. Operating in both the USA and UK, Elaitra aims to improve diagnostic accuracy and outcomes in breast cancer care.
BioCaptiva
Seed Round in 2022
BioCaptiva is a company focused on advancing liquid biopsy technology for the early diagnosis and monitoring of challenging-to-detect cancers. The company's innovative platform captures circulating free DNA from patients' blood in greater quantities than existing methods, addressing the limitations of current liquid biopsy tests. By enhancing the ability to detect and monitor cancer, BioCaptiva aims to provide healthcare professionals with improved tools for disease management, ultimately transforming the landscape of cancer diagnostics.
Achilles Therapeutics
Seed Round in 2016
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.
GammaDelta Therapeutics
Seed Round in 2016
GammaDelta Therapeutics focuses on developing innovative immunotherapies utilizing gamma delta (γδ) T cells to treat cancer and autoimmune diseases. The company aims to harness the unique properties of tissue resident γδ T cells to enhance the effectiveness of immunotherapy. By leveraging these specialized immune cells, GammaDelta Therapeutics seeks to provide patients with improved treatment options that can significantly impact their health outcomes in the face of serious diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.